Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

NCT02698579 is registered in ClinicalTrials.gov with Genetix Biotherapeutics Inc. as lead sponsor.

NCT NCT02698579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02698579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
Lead sponsor
Genetix Biotherapeutics Inc.
Phase
Observational
Overall status
Active, not recruiting
Start date
January 22, 2016
Completion date
August 31, 2038
Enrollment
64 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

adrenoleukodystrophy (ald), cerebral adrenoleukodystrophy (cald), x-linked adrenoleukodystrophy (x-ald)